Introduction
============

Hypersecretion of proinflammatory cytokines (tumor necrosis factor-α, interleukin (IL)-1, and IL-6) in overweight and obese individuals can cause insulin resistance in peripheral tissues ([@r1]-[@r4]), as well as a decline in beta cell mass and function ([@r5]-[@r7]), thus promoting development of type 2 diabetes. Presumably, this effect can be countered by anti-inflammatory cytokines such as IL-10, transforming growth factor-β, and adiponectin ([@r8]-[@r12]). Hence, the possibility exists that an imbalance in the activity of pro- and anti-inflammatory cytokines has an important role in the pathogenesis of type 2 diabetes.

Polymorphisms in pro- and anti-inflammatory cytokine genes, as well as their receptors, may exacerbate this cytokine imbalance and thus also development of type 2 diabetes ([@r13]-[@r16]). On the basis of genotype, there are 'high' and 'low'cytokine producers. By identifying specific polymorphisms in each cytokine gene, it is possible to identify high and low cytokine producers by genotype. Therefore, in certain individuals, a genetic predisposition for a hyper-reactive immune response may be responsible for the development of type 2 diabetes. Furthermore, the progression of microvascular complications ([@r16]-[@r18]) may be associated with polymorphisms in pro- and anti-inflammatory cytokine genes. However, it has not been established whether the intensity of the immune response during diabetes-associated chronic inflammation affects the development and/or progression of type 2 diabetes and its characteristic microvascular complications.

Interleukin-10 is a primary anti-inflammatory cytokine, and according to previous reports, a decrease in its secretion is associated with obesity and metabolic syndrome, as well as hyperglycemia and type 2 diabetes ([@r8], [@r9], [@r13], [@r19]). The IL-10 gene is located in the 1q32.1h genomic region. Within this region, a point mutation (G to A) at position -1082 is linked to low IL-10 expression ([@r13], [@r19], [@r20]). The objective of this study was to determine the frequency of the IL-10 gene polymorphism, -1082G/A, in overweight/obese patients with type 2 diabetes compared to overweight/obese non-diabetic controls, and to determine the possible link between this polymorphism and the fundamental pathophysiological complications of type 2 diabetes such as insulin resistance, reduced beta cell function, and microvascular dysfunction.

Materials and Methods
=====================

Study design
------------

This was a cross-sectional study that included 240 subjects. The experimental group consisted of 144 overweight or obese patients with type 2 diabetes, and the control group included 96 age- and sex-matched overweight or obese individuals without type 2 diabetes. Subjects were recruited from the outpatient population visiting Regional Center for Endocrinology and Metabolism Disorders, Osijek University Hospital Centre in Osijek and primary care physician practices in the Osijek-Baranja County, Croatia from 2010 to 2013. This study complied with the Declaration of Helsinki and was approved by the Ethics Committee of the Osijek University Hospital Centre (reference number 29-1:6663/06). A written informed consent was obtained from each patient.

Patient inclusion criteria
--------------------------

The experimental group was required to meet the following inclusion criteria: diagnosis of type 2 diabetes; diabetes treated with diet, exercise, or medications (not thiazolidinediones or insulin therapy); excessive body weight (body mass index (BMI) \>25 kg/m^2^); and age 18-80 years. In the control group, type 2 diabetes was excluded based on the fasting glucose (\<7 mmol/L) and glycated hemoglobin (HbA1c; \<6.5%) levels, according to the recommendations of the American Diabetes Association, International Diabetes Federation, and European Association for the Study of Diabetes. Patients with a history of the following conditions were excluded from the study: type 1 diabetes; diabetes treated with insulin therapy; recent acute infection regardless of localization; long-term treatment with immunomodulatory and anti-inflammatory drugs; long-term therapies with possible pro-diabetic effects such as glucocorticoids, immunosuppressive drugs, and certain antidepressants used over a period of 3 months; endocrine disorders with secondary diabetes; other intercurrent diseases associated with acute or chronic inflammation; history of acute pancreatitis or chronic pancreatitis; history of acute or chronic B or C hepatitis or HIV; or malignant disease within the past 5 years.

Methods
-------

At study entry, medical history was obtained that included demographics, family history, disease diagnosis, risk factors for type 2 diabetes, presence of chronic complications, other relevant diseases, medications, and lifestyle habits. Physical examination was performed with standardized measurement of body weight, body height, waist circumference, and blood pressure. BMI was calculated from body weight and height (kg/m^2^). In addition, blood and urine samples were collected for biochemical analyses (fasting glucose, HbA1c, liver enzymes, lipid profile, creatinine, uric acid, total proteins, albumins, leukocytes, C-reactive protein (CRP), plasminogen activator inhibitor-1 \[PAI-1\], and fibrinogen), evaluation of complications (endogenous creatinine clearance, 24**-**hour urine protein, and 24**-**hour urine albumin excretion), hormone analysis (insulin, C-peptide, thyroid-stimulating hormone (TSH), cortisol, sex hormone binding globulin (SHBG)), and DNA isolation, to determine the presence and effects of the gene polymorphism. All patients underwent neurological and ophthalmological examinations. Biochemical and urine analyses were performed using established methods in the Central Laboratory of the Osijek University Hospital Centre.

To assess glucose metabolism, the following parameters were chosen: fasting glucose, HbA1c, insulin, C-peptide, homeostatic model assessment index of insulin resistance (HOMA-IR), and homeostatic model assessment index of beta cell function (HOMA-B). HOMA-IR and HOMA-B were calculated using the following formulae: HOMA-IR = glucose (mmol/L) × insulin (mIU/L)/22.5; HOMA-B = 20 × insulin (mIU/L)/(glucose − 3.5)%.

All samples for hormone analysis were centrifuged and frozen at -20 °C. Hormone levels (insulin, C-peptide, cortisol, TSH and SHBG) were determined using the radioimmunoassay method with commercially available kits, according to the manufacturer's recommendations (DIAsource Immuno Assays S.A., Louvain-la-Neuve, Belgium).

Genomic DNA was extracted from 200 µL of peripheral whole blood with EDTA as an anticoagulant. Commercially available spin columns for DNA extraction were used for DNA extraction, according to the manufacturer's instructions (G-spin TN Genomic DNA Extraction Kit; Intron Biotechnology, Seoul, South Korea).

Genotypic analysis of the IL-10 gene polymorphism, -1082G/A (rs1800896), was performed using TaqMan® SNP Genotyping Assay (Assay ID: C\_\_\_7514879_10) with an ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA).

Thermocycler parameters were as follows: 95 °C for 10 min (hold); 40 cycles at 92 °C for 15 s (denaturation), 60 °C for 1 min (primer annealing and extension). Negative and positive control samples were run simultaneously in each real-time PCR plate analyzed. The total reaction volume *per* well was 25 µL with 5 µL of DNA (1 ng/µL) used as a template.

Statistical analysis
--------------------

Results were analyzed using descriptive statistical analysis. Continuous variables were summarized using sample size, mean, median, standard deviation, and minimum and maximum values. Significance was declared at a two-sided 0.05 level, unless otherwise specified. Student's *t*-test was used as a parameter test and Mann-Whitney as a non-parameter test to calculate distribution differences for continuous variables. The χ^2^-test and Fisher exact tests were used for variables measured by a nominal or ordinal scale. To detect differences in the distributions of three or more variables, the ANOVA test (parameter test) and Friedman ANOVA test (non-parameter test) were utilized. In addition, factorial analysis of variables was used in which one variable was a specific group (experimental or control), and the other was the cytokine genotype. The Hardy-Weinberg equilibrium (deviation of expected genotype frequencies -- p ([@r2]) + 2pq + q ([@r2]), where pq represents the frequency of one of two possible alleles, biallelic single nucleotide polymorphism (SNP)) was tested with the χ^2^-test with one degree of freedom and significance at p\<0.05. Statistical analysis was performed using Statistica 9.1 (StatSoft Inc., Tulsa, OK, USA, 2012).

Results
=======

The baseline characteristics of the subjects are summarized in [Table 1](#t1){ref-type="table"}. Both groups were similar in age and sex. Body weight (p=0.012), BMI (p=0.018), and waist circumference (p=0.026) were significantly higher in the controls when compared to patients with diabetes. Fasting glucose and HbA1c values were higher (p\<0.00001 and p\<0.00001, respectively) in patients with type 2 diabetes, while insulin and C-peptide values were similar in both groups. HOMA-IR was significantly higher (p=0.000083) and HOMA-B (p=0.022) significantly lower in diabetic group than in control group. Lipid profile analysis revealed that triglyceride levels were higher (p=0.014) in diabetic group, while high-density lipoprotein (p=0.0045), low-density lipoprotein cholesterol (p\<0.00001) and total cholesterol levels (p=0.00037) were lower in patients with diabetes than in control group, most likely as a consequence of treatment with statins in the former. Diabetic group had higher levels of leukocytes (p=0.012), fibrinogen (p=0.049) and PAI-1 (p=0.009), and lower levels of albumin (p=0.001) than control group. CRP levels were also higher in patients with diabetes, but the difference was only numerical and not statistically significant.

###### Baseline characteristics of study subjects

  -----------------------------------------------------------------------------------------
  Baseline characteristic            Type 2 diabetes\      Control\             p-value
                                     (n=143)               (n=96)               
  ---------------------------------- --------------------- -------------------- -----------
  Age (years)                        60.1±10.3             58.8±8.4             NS

  Age at diagnosis (years)           52.1±11.4                                  0.000001

  Sex: male, n (%) female, n (%)     63 (44)\              30 (32)\             NS\
                                     80 (56)               60 (68)              0.056

  Body weight (kg)                   89.1±19.6             95.9±20.8            0.012

  Body mass index (kg/m^2^)          32.17±5.49            34.04±6.43           0.018

  Waist circumference (cm)           103.4±12.8            107.5±13.8           0.026

  Systolic blood pressure (mm Hg)    135±18                140±18               0.04

  Diastolic blood pressure (mm Hg)   83±11                 86±9                 NS

  Fasting glucose (mmol/L)           10.5±4,2              5.1±0.7              \<0.00001

  HbA1c (%)                          9.37±2.35             5.86±0.28            \<0.00001

  Insulin (mIU/L)                    14.17 (7.17-15,2)\*   12.99 (8.8-17.8)\*   NS

  C-peptide (pmol/L)                 1,106.7±559.1         1,192.8±596.8        NS

  HOMA-IR                            4.60 (3.35-6.3)\*     3.52±2.71            0.00008

  HOMA-B                             30.09 (17.7-76,5)\*   210.4±126.7          0.022

  Cholesterol (mmol/L)               5.34±1.58             6.19±1.38            0.00037

  Triglycerides (mmol/L)             2.07 (1.58-2.67)\*    1.83±1.05            0.014

  HDL cholesterol (mmol/L)           1.19±0.49             1.35±0.34            0.0045

  LDL cholesterol (mmol/L)           3.08±1.24             4.06±1.18            \<0.00001

  L (×10^9^ cells/L)                 7.2±2.2               6.5±1.7              0.012

  CRP (mg/L)                         3.0 (1.3-5.6)\*       3.1 (1.4-7.2)\*      NS

  Fibrinogen (g/L)                   3.93±1.06             3.70±0.84            0.049

  PAI-1 (U/L)                        4.19±1.82             3.49±1.99            0.009

  Albumin (g/L)                      42.60±3.43            44.13±2.70           0.001
  -----------------------------------------------------------------------------------------

t-test; NS = nonsignificant; HOMA-IR = homeostatic model assessment index of insulin resistance; HOMA-B = homeostatic model assessment index of beta-cell function; HDL = high-density lipoprotein; LDL = low-density lipoprotein; L = leukocytes; CRP = C-reactive protein; PAI-1 = plasminogen activator inhibitor-1; \*values represented as median (interquartile range)

Investigation of IL-10 gene polymorphisms revealed that genotypes did not significantly deviate from Hardy-Weinberg equilibrium (IL-10-1082G/A (rs1800896); p=0.941) indicating that in the experimental population, the effects of selection, genetic drift, mutations, gene flow, and migration were not present. The frequency of the minor allele was 0.427 (42.7%) in all subjects. The IL-10-1082G/A genotype distribution in diabetic group was as follows: GG homozygous, 29.37%; GA heterozygous, 55.94%; and AA homozygous, 14.69%. The genotype distribution in control group was as follows: GG homozygous, 32.29%; GA heterozygous, 50.0%; and AA homozygous, 17.71%. There was no significant difference in genotype distribution between the two groups (p=0.654).

In order to evaluate the effect of the IL-10 genotype on glucose metabolism, the mean values of fasting glucose, HbA1c, HOMA-IR and HOMA-B were first compared between the diabetic and control groups ([Fig. 1](#f1){ref-type="fig"}). These values were then compared between different IL-10 genotypes including all subjects (experimental and control) ([Fig. 2](#f2){ref-type="fig"}), and finally with the genotype and group affiliation combined ([Fig. 3](#f3){ref-type="fig"}). The mean levels of fasting glucose (p\<0.000001), HbA1c (p\<0.000001) and HOMA-IR (p=0.004312) were significantly higher, while the mean HOMA-B (p=0.047508) levels were lower in patients with diabetes than in controls, as expected ([Fig. 1](#f1){ref-type="fig"}). Analysis of the mean fasting glucose and HbA1c levels in subjects with the AA genotype ('low producers' of IL-10) yielded significantly higher values (p\<0.000001) of both parameters in control and diabetic subjects. Anti-inflammatory effects were expected to be lowest in this group ([Fig. 2](#f2){ref-type="fig"}). The interaction effect was not statistically significant, indicating that the effect of a specific IL-10 genotype on the phenotype, in this case fasting glucose and HbA1c, was independent of the presence of type 2 diabetes ([Fig. 3](#f3){ref-type="fig"}).
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The mean HOMA-IR values were significantly lower (p=0.003632) in subjects with the GG genotype ('high producers' of IL-10) in both groups, in which the expected anti-inflammatory response was strongest ([Fig. 2](#f2){ref-type="fig"}). In contrast, the mean HOMA-B values were lowest (p=0.000178) in subjects with the AA genotype ('low producers') with a diminished IL-10 anti-inflammatory response ([Fig. 2](#f2){ref-type="fig"}). Again, the interaction effect was not statistically significant; that is, the effect of a specific IL-10 genotype on HOMA-IR and HOMA-B did not depend on the presence of type 2 diabetes ([Fig. 3](#f3){ref-type="fig"}).

In order to investigate whether the described association of the IL-10 genotype and glucose metabolism parameters was a consequence of other risk factors (phenotype characteristics), analysis of the groups with different genotypes encompassing all subjects was performed in relation to sex, age and anthropometric characteristics ([Table 2](#t2){ref-type="table"}). There was no statistically significant difference between subjects with different genotypes for the IL-10-1082G/A polymorphism according to age, sex, waist circumference, or BMI.

###### Analysis of groups with different genotypes according to sex, age, waist circumference and body mass index (BMI)

  Phenotype characteristic     Genotype -1082A/G IL-10   p-value                   
  ---------------------------- ------------------------- ------------ ------------ ------
  GG                           GA                        AA                        
  \*Age (years)                59.4±9.4                  59.4±10.2    60.1± 8.0    0.92
  Female: n (%)                40 (55)                   82 (64)      24 (63)      0.41
  Male: n (%)                  33 (45)                   46 (36)      14 (37)      
  \*Waist circumference (cm)   105.6±14.4                105.5±14.4   102.8±11.1   0.54
  \*BMI (kg/m^2^)              33.2±5.9                  32.8± 6.4    32.7 ± 5.9   0.86

\*Data shown as mean ± SD; t-test, χ^2^-test

In addition, analysis of chronic microvascular complications (24-hour protein and albumin excretion, proliferative and non-proliferative diabetic retinopathy, and diabetic polyneuropathy) in relation to a specific IL-10 genotype was performed ([Table 3](#t3){ref-type="table"}). There was no statistical significance in the development of microvascular complications between the groups with different IL-10 polymorphism genotypes.

###### 24-hour protein and albumin excretion, diabetic retinopathy and polyneuropathy according to IL-10 genotype

  Diabetic complication                   Genotype -1082A/G IL-10   p-value                              
  --------------------------------------- ------------------------- -------------- -------------- ------ ------
  GG                                      GA                        AA                                   
  \*24-h urine protein excretion (mg/L)   168.37±167.4              326.7±626.98   211.0±262.65   0.58   
  \*24-h urine albumin excretion (mg/L)   36.68±109.14              111.2±293.4    52.20±134.67   0.69   
  Diabetic retinopathy                    Yes (%)                   16             11             12     0.83
  No (%)                                  84                        89             88                    
  Diabetic polyneuropathy                 Yes (%)                   62             70             72     0.72
  No (%)                                  38                        30             28                    

\*Data shown as mean ± SD; t-test, χ^2^-test

Discussion
==========

Insulin resistance and beta cell function have a key role in the pathogenesis of type 2 diabetes. Results of the UK Prospective Diabetes Study demonstrated that impaired beta cell function was crucial for the development and progression of type 2 diabetes ([@r21]), while other studies implicated proinsulin secretion ([@r22]), decline of beta cell mass ([@r23]), and amyloid deposition ([@r24]). In our study, patients with type 2 diabetes had higher HOMA-IR and lower HOMA-B values, clearly demonstrating two key elements of the pathophysiology of type 2 diabetes, i.e. insulin resistance and impaired beta cell function. Concentrations of basal insulin and C-peptide were similar in both groups, probably as a result of compensatory insulinemia due to insulin resistance in patients with diabetes.

Current research in obese individuals indicates that the healthy obese population has low inflammatory activity as opposed to obese patients with metabolic syndrome ([@r25]-[@r27]). These findings support our study where we found that specific parameters of inflammatory activity, such as leukocyte count, fibrinogen, serum albumin, and PAI-1 levels, were lower in control subjects than in patients with diabetes ([@r28]-[@r32]). All markers of inflammation were increased in obese diabetic subjects except for CRP levels, where difference between the experimental and control groups was not statistically significant. Presumably, it was due to variations in the sensitivity of CRP and circulating CRP levels between the groups.

Direct association of the IL-10-1082G/A polymorphism and type 2 diabetes remains elusive. Results of a meta-analysis published in 2013, which included 10 studies, demonstrated that the IL-10-1082G/A polymorphism was clearly associated with type 2 diabetes, but only in Asian, and not in European or African populations ([@r13]). Our observation that the frequency of different IL-10 genotypes did not vary between the control and diabetic groups was in agreement with this analysis. However, when contemplating diabetes-related traits in all subjects (control and diabetic) of a specific genotype, it is clear that the HOMA-IR values were higher and HOMA-B values lower in the group with the AA genotype ('low producers') than in the groups with GG or GA genotypes. Our control group consisted of obese subjects without diabetes but the criteria we applied for diabetes exclusion (fasting glucose \<7 mmol/L, HbA1c \<6.5%) resulted in the inclusion of so-called 'intermediate' patients with pre-diabetes in our control group. Since this particular subset of patients has a higher risk of developing type 2 diabetes ([@r33]), we can speculate that the AA genotype of the IL-10 gene may occur at a higher frequency in patients with pre-diabetes than in healthy individuals. However, diabetes-related traits have not been fully established, thus influencing the final results of this study. The influence of SNP polymorphism in pre-diabetes should be investigated in further studies with a larger number of subjects.

Contrary to our results, a study performed by Scarpelli *et al*. in an Italian cohort found no association between IL-10-1082G/A and diabetes-related traits (fasting glucose, HOMA-B and HOMA-IR) ([@r19]). This discrepancy may be attributed to ethnic variations regarding the prevalence of specific polymorphisms in the IL-10 gene, as our patients were recruited solely from eastern Croatia. Indeed, this is the first report on the frequency of the IL-10-1082G/A SNP in the Croatian population, and it is similar to previous reports for the European population (42.7% and 46.9%, respectively) ([@r13]). However, in the study by Scarpelli *et al*. ([@r19]), the link between AA genotype, fasting insulin and insulin resistance is reported with more prominent -592C/A, but not the -1082G/A, IL-10 promoter polymorphism. Therefore, it is possible that in the Croatian population, the -1082G/A polymorphism is more prominent and contributes to the interindividual variation in BMI and insulin sensitivity.

In a study performed by Kolla *et al*., development of diabetic polyneuropathy was associated with high production of IL-10 (genotype -1082G/G) ([@r16]), while Lee *et al*. demonstrated that high concentrations of IL-10 negatively correlated with diabetic retinopathy ([@r18]). However, we did not establish any difference in the development of microvascular complications between different IL-10 polymorphism genotypes, presumably due to a small sample size.

The present study had several limitations. The patient population was relatively small and recruited exclusively from eastern Croatia. This small patient population may have influenced study results, where IL-10 polymorphism genotypes were associated with diabetes-related traits but not with diabetes or its microvascular complications. Furthermore, standard statistical analysis of the secondary phenotype data in case-control studies can be misleading since the association between a secondary phenotype and a genetic variant in the case and control groups can be quite different from their association in the general population, requiring a novel approach in statistical analysis ([@r34]). In addition, since this was a cross-sectional study, disease outcome and prognosis in relation to a specific genotype is still unknown. Thus, a large-scale, long-term, prospective, population-based study with different ethnicities is required to establish whether a relationship between polymorphisms in the IL-10 gene and type 2 diabetes actually exists and whether it affects the prognosis of type 2 diabetes and development of microvascular complications.

Conclusions
===========

In conclusion, obese patients with type 2 diabetes showed an increased inflammatory activity when compared to obese non-diabetic controls. We could not show the association between the IL-10-1082G/A SNP genotypes and development of type 2 diabetes and microvascular complications. However, we established a clear link between the IL-10-1082G/A polymorphism and diabetes-related traits, therefore specific genotypes (high producers *vs*. low producers) had a distinct impact on diabetes-related traits in all subjects.
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